BIO Announces Initial Companies Selected to Present at the Seventh Annual Bio® Investor Forum

Press Contact: Erin Reese



Investor Contact: John Craighead, Ph.D.


WASHINGTON, D.C. (Tuesday, September 16, 2008) - The Biotechnology Industry Organization (BIO) today announced the first 76 companies selected through a competitive screening process to present at the Seventh Annual BIO Investor Forum.  Presenting companies will be asked to focus on near-term clinical catalysts and accomplishments across therapeutic fields and areas of unmet medical need.  

A total of 190 presenting companies will be selected and posted on the conference website on a rolling basis.  To view the latest list, please visit

Select late-stage private and emerging public biotech companies were nominated by an Advisory Committee, comprised of members from top-tier firms from the buy-side, sell-side, venture capital and private equity communities:

  • Gaurav Aggarwal, M.D., Panorama Capital
  • Ashley Dombkowski, Ph.D., MPM Capital
  • Rishi Gupta, J.D., OrbiMed Advisors, LLC
  • William Ho, Banc of America Securities, LLC
  • Ron Laufer, M.D., Visium Asset Management
  • George Milstein, Pacific Growth Equities, LLC
  • Matthew Perry, Biotechnology Value Fund, LP
  • Michael Wasserman, Ph.D., H.I.G. Ventures 

“These clinical-stage companies represent the industry’s most innovative therapeutic advances and potential investment opportunities,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Companies nominated by our Advisory Committee are also distinguished by significant near-term clinical, regulatory and corporate catalysts.”

The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies.  The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts.  In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.


This year’s meeting will continue to explore current and competitive therapeutic development trends and investment opportunities in life sciences through therapeutic, business and plenary panels. The conference will also feature BIO’s web-based partnering system to arrange one-on-one meetings between registered companies, investors, and industry business development, licensing and therapeutic franchise heads.


To learn more about the BIO Investor Forum, including registration and program information, please visit  Registration is complimentary for qualified investors and credentialed members of the media.


The following companies will present at the Seventh Annual BIO Investor Forum:


Acadia Pharmaceuticals Inc. (ACAD)

Acceleron Pharma, Inc.

Acologix, Inc.

Acucela Inc.


Affymax Inc. (AFFY)

Allon Therapeutics Inc. (NPC)

Alnylam Pharmaceuticals (ALNY)

Amira Pharma

Anadys Pharmaceuticals Inc (ANDS)

Arana Therapeutics Limited (ATPCF)

Ardea Biosciences, Inc. (RDEA)

Athersys, Inc. (ATHX)

AVANT Immunotherapeutics, Inc. (AVAN)

Bayhill Therapeutics

Biolex Therapeutics

BioMimetic Therapeutics Inc (BMTI)

BiPar Sciences


CardioVascular BioTherapeutics Inc (CVBT)

Celator Pharmaceuticals, Inc.

Cell Therapeutics Inc (CTICD)


CombinatoRx Inc (CRXX)

Curis Inc (CRIS)

CytRx Corporation (CYTR)


Elixir Pharmaceuticals


Geron Corporation (GERN)


Glycomimetics, Inc.

Halozyme Therapeutics Inc (HALO)

Hemispherx Biopharma Inc (HEB)

Hollis-Eden Pharmaceuticals Inc (HEPH)

Hydra Biosciences

Icagen Inc (ICGN)

ImmunoGen, Inc. (IMGN)

ISTA Pharmaceuticals Inc (ISTA)

KAI Pharmaceuticals, Inc

Karo Bio AB (KARO.ST)


Metabasis Therapeutics Inc (MBRX)


MethylGene Inc (MYLGF.PK)

Micromet Inc (MITI)

Molmed SpA (MTA:MLM)

Nabriva GMBH

Napo Pharmaceuticals Inc. (NAPL.L)


Nile Therapeutics, Inc (NLTX)

Northwest Biotherapeutics Inc (NWBO.OB)

Oncolytics Biotech Inc (ONCY)

Oncothyreon Inc. (ONTY)

Pacific Biosciences

Peplin (PEPBF.PK)

Peregrine Pharmaceuticals Inc (PPHM)


Portola Pharmaceuticals

Presidio Pharmaceuticals

Proteolix, Inc.

QuatRx Pharmaceuticals

Reata Pharmaceuticals

Regulus Therapeutics


Sunesis Pharmaceuticals Inc.(SNSS)

Supernus Pharmaceuticals


Synageva BioPharma Corp

Syndax Pharmaceuticals

Targeted Genetics Corp (TGEN)

Tobira Therapeutics

Tranzyme Pharma

Wilex AG (WL6.DE)


Zelos Therapeutics

Upcoming BIO Events

Intellectual Property Council Committee Fall Conference and Meeting
October 20-22, 2008
Orlando, Fla.

BIO HR Conference 2008
October 26-28, 2008
San Diego, Calif.

BIO-LES Advanced Business Development Course
October 27-29, 2008
San Francisco, Calif.

BIO Investor Forum 2008
October 29-31, 2008
San Francisco, Calif.

Advanced Business Development Course
November 14-16, 2008
Mannheim/Heidelberg, Germany

BIO-Europe 2008
November 17-19, 2008
Mannheim/Heidelberg, Germany

2009 BIO International Convention
May 18-21, 2009
Atlanta, Ga.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.